DBV Technologies reported $194.45M in Equity Capital and Reserves for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
DBV Technologies DBVT:US USD 194.45M 17.6M
Acadia Pharmaceuticals ACAD:US USD 400.41M 25.27M
Alnylam Pharmaceuticals ALNY:US USD -158223000 90.58M
Amarin AMRN:US USD 587.83M 7.78M
Biocryst Pharmaceuticals BCRX:US USD -294597000 51.94M
Biomarin Pharmaceutical BMRN:US USD 4.6B 34.64M
Esperion Therapeutics ESPR:US USD -323778000 29.68M
Galectin Therapeutics GALT:US USD -22335000 7.11M
Halozyme Therapeutics HALO:US USD 169.8M 72.81M
Insmed INSM:US USD 87.95M 117.91M
Intercept Pharmaceuticals ICPT:US USD 93.08M 14.6M
Neurocrine Biosciences NBIX:US USD 1.71B 163.2M
Ptc Therapeutics PTCT:US USD -347086000 120.18M
Sarepta Therapeutics SRPT:US USD 384.95M 45.89M
Ultragenyx Pharmaceutical RARE:US USD 352.49M 116.34M
United Therapeutics UTHR:US USD 4.8B 234.5M
YTE INCY:US USD 4.37B 143.47M